U.S. Pharma Stock News

Freddie Mac (FMCC) released its latest Primary Mortgage Market Survey, showing the 30 year fixed mortgage rate holding around 6%, near its lowest level since 2022, with refinancing and purchase applications ahead of last year. See our latest analysis for Federal Home Loan Mortgage. Even with investor interest tied to steadier mortgage rates, Federal Home Loan Mortgage’s recent share price return has been weak, with a 30 day share price return of 15.27% and a 90 day share price return of a...

If you are wondering whether Tapestry is still worth considering after a strong run, the key question now is how the current share price stacks up against its underlying value. The stock has been volatile recently, with a 6.8% decline over the last 7 days, a 17.8% gain over 30 days, 15.9% year to date, 95.3% over 1 year, and a very large return over 3 and 5 years. Recent coverage of Tapestry has focused on its position in the branded accessories and apparel space and how investors are...

If you are wondering whether Broadcom's current share price still reflects good value after its long run, or if the easier gains are already behind it, you are not alone in asking that question. Broadcom shares last closed at US$332.77, with returns of 4.1% over 7 days, 8.0% over 30 days, a 4.3% decline year to date, a very strong 72.2% return over the past year, an extremely high 3 year return, and a 5 year return of around 7x. Recent headlines around Broadcom have focused heavily on its...

flyExclusive (FLYX) FY 2025 results: higher revenue with ongoing losses flyExclusive (FLYX) has reported another quarter of growth in scale, with Q4 FY 2025 revenue at US$104.3 million and a basic EPS loss of US$0.22, while trailing twelve month revenue reached US$375.9 million against a full year basic EPS loss of US$1.01. The company has seen quarterly revenue move from US$76.9 million in Q3 FY 2024 to US$104.3 million in Q4 FY 2025, with basic EPS losses ranging between US$0.22 and US$0.32...

FactSet Research Systems (NYSE:FDS) has rolled out new AI driven financial crime risk management tools within its core Workstation platform. The company has also named a Chief AI Officer and a new Chief Technology Officer to concentrate leadership around AI focused product development. These steps align product capabilities and executive oversight around AI for compliance, risk monitoring and client productivity. FactSet Research Systems, trading at $224.92, is moving deeper into AI...

What RLI’s Recent Returns Tell You Right Now RLI (RLI) has attracted fresh attention after a period where the share price has moved in different directions over recent time frames, with modest gains in the past month but weaker performance over the past year. See our latest analysis for RLI. At a share price of US$61.34, RLI’s recent 30-day share price return of 2.83% contrasts with a 1-year total shareholder return decline of 15.48%, which hints that momentum has cooled after a stronger...

Antalpha Platform Holding (NasdaqGM:ANTA) has capped FY 2025 with fourth quarter revenue of about US$28.0 million and basic EPS of US$0.39, set against trailing 12 month revenue of roughly US$79.7 million and EPS of US$0.84 that are reported to be up very strongly year over year. The company has seen quarterly revenue move from around US$13.4 million in Q4 2024 to US$28.0 million in Q4 2025, while basic EPS over that same period shifted from US$0.09 to US$0.39, and trailing net profit margin...

CrowdStrike Holdings (NasdaqGS:CRWD) is partnering with Schwarz Digits to bring its AI native Falcon cybersecurity platform to Europe’s STACKIT sovereign cloud. The collaboration focuses on supporting GDPR and regional data sovereignty requirements across European markets. By integrating Falcon into STACKIT, CrowdStrike is aiming at highly regulated industries that prioritize data residency and operational autonomy. CrowdStrike, known for its cloud delivered Falcon security platform, is...

If you are looking at Mosaic and wondering whether the current share price really reflects its underlying worth, this article will walk through what the numbers actually say. The stock recently closed at US$26.28, with returns of 8.7% over 1 year and 5.0% year to date, set against declines of 3.2% over the last week and 7.2% over the last month, so the market’s view on the company has not been one way. Recent news flow around Mosaic has largely focused on broader sector themes and company...

Rigetti Computing (RGTI) has wrapped up FY 2025 with Q4 revenue of about US$1.9 million and a basic EPS loss of US$0.06, alongside a trailing twelve month EPS loss of US$0.70 and revenue of roughly US$7.1 million. Over the past six quarters, revenue has moved in a tight band between US$1.5 million and US$2.4 million, while quarterly basic EPS has swung from a profit of US$0.15 in early 2025 to losses as wide as US$0.68. This sets the scene for a story that is still heavily driven by top line...

INVO Fertility has joined the Progyny (NasdaqGS:PGNY) provider network, adding its clinic to Progyny's fertility benefits platform. The partnership expands access to employer sponsored fertility care for patients in Wisconsin and nearby regions. This development broadens Progyny's provider footprint and increases potential touchpoints with covered employees seeking fertility treatment. Progyny runs a fertility benefits platform that connects employer sponsored health plans with a network of...

Recent insider filings at Molina Healthcare (MOH) show sizable share purchases by several top executives, a cluster of buying that often draws investor attention to management’s alignment with shareholders. See our latest analysis for Molina Healthcare. At a share price of US$147.71, Molina Healthcare’s recent 30‑day share price return of an 18.57% decline and year‑to‑date share price return of a 17.23% decline contrast with a much steeper 1‑year total shareholder return decline of 54.39%...

Tempus AI (TEM) shares are back in focus after the company expanded its multi year collaboration with Merck, placing Tempus’ de identified data and Lens AI platform at the center of Merck’s precision oncology research. See our latest analysis for Tempus AI. Tempus AI’s latest collaboration news comes after a choppy few months for the stock, with a 1 day share price return of 3.43% lifting it to US$53.05. Over the last 90 days, the share price has declined 30.8%, which contrasts with an 8.58%...

ACRES Commercial Realty (ACR) just closed out FY 2025 with fourth quarter total revenue of US$21.3 million and basic EPS of US$0.03 on a trailing twelve month basis, setting a tight spotlight on how its income stream is holding up. Over the past six reported quarters, total revenue has moved within a band of US$18.7 million to US$25.0 million per quarter, while quarterly basic EPS has ranged from a loss of US$0.80 to a gain of US$1.38, giving investors a wide spread of outcomes to parse. With...

In late February and early March 2026, Gen Digital expanded its cyber safety reach as MoneyLion launched LifeLock-powered identity protection for its members and Norton rolled out the Genie AI scam-protection assistant directly within ChatGPT, helping users assess emails, messages, images, and links in real time. Together, these launches highlight how Gen Digital is embedding its security and identity protection tools into partner platforms and everyday AI use, potentially deepening user...

In early March 2026, Roblox Corporation rolled out AI-driven real-time chat rephrasing and upgraded text filters to keep in-game conversations civil while more accurately detecting attempts to bypass its Community Standards across multiple languages and age-checked groups. This push to make communication smoother and safer highlights how central trust and moderation technology have become to Roblox’s effort to support large-scale user engagement and creator-driven experiences. Next, we'll...

Vertex Pharmaceuticals recently reported Phase 4 data showing its non-opioid pain signal inhibitor JOURNAVX (suzetrigine) enabled effective, mostly opioid-free recovery for adults with moderate-to-severe acute pain after a range of plastic surgeries, with results being presented at the AAPM PainConnect 2026 meeting in Salt Lake City. The findings suggest JOURNAVX could become an important component of multimodal post-surgical pain care, potentially reducing dependence on opioids in aesthetic...

REGENXBIO (RGNX) closed out FY 2025 with Q4 revenue of US$30.3 million and a basic EPS loss of US$1.30, alongside a trailing twelve month EPS loss of US$3.76 on revenue of US$170.4 million. Over recent periods, the company has seen quarterly revenue range from US$21.4 million to US$89.0 million, while basic EPS has swung between a small profit of US$0.12 and losses of more than US$1.30 per share. This sets up a story that is heavily driven by how much investors are prepared to tolerate...

For readers considering whether RH at around US$151.61 reflects an appropriate balance between potential upside and the risks involved, or whether the market has moved too far in the other direction, this article will help frame that question using a valuation lens. The stock has experienced sharp moves recently, with a 7 day return of an 18.8% decline, a 30 day return of a 24.0% decline, and a year to date return of a 21.6% decline. The 1 year return stands at a 46.0% decline and the 5 year...

Hesai Group (HSAI) drew fresh attention after shareholders approved wide ranging governance and capital measures, including new articles of association, redesignated Class B shares and expanded authority for directors to issue and repurchase stock. See our latest analysis for Hesai Group. The governance and capital moves come after a sharp pullback, with a 1 day share price return of a 6.35% decline and a 7 day share price return of a 12.84% decline, even though the 90 day share price return...

If you are wondering whether S&P Global's current share price still offers value, you are not alone. This article will walk through what the market might be pricing in and what that could mean for you. The stock last closed at US$451.11, with returns of 3.1% over the past 7 days, a 3.7% decline over 30 days, a 12.0% decline year to date, an 11.6% decline over 1 year, and gains of 38.4% and 36.3% over 3 and 5 years respectively. Recent coverage around S&P Global has focused on its role as a...

Savant Wealth Management entered into a partnership with Heritage Financial, integrating Heritage's leadership and many employee-owners into Savant's ownership structure. The combination expands Savant's presence in Massachusetts and brings Heritage Financial, traded as NasdaqGS:HFWA, into closer alignment with Savant's operations. For you as an investor, this ties a regional wealth manager more closely to a larger advisory platform, while keeping Heritage Financial's client relationships...

Atlassian (TEAM) is back in focus after launching the open beta of AI agents in Jira and ramping up its Model Context Protocol efforts, a move that has coincided with a rebound in investor sentiment. See our latest analysis for Atlassian. The launch of AI agents in Jira and new MCP investments comes after a difficult period for the stock, with a 30-day share price return of a 21.42% decline and a 1-year total shareholder return showing a 67.08% loss. However, the recent 1-day gain of 7.42%...

Cross Country Healthcare (CCRN) has capped FY 2025 with Q4 revenue of US$236.8 million and a basic EPS loss of US$2.56, alongside a Q4 net loss of US$82.9 million. On a trailing twelve month basis, revenue was US$1.1 billion with a basic EPS loss of US$2.93 and a net loss of US$94.9 million. Over recent quarters, revenue has moved from US$315.1 million and basic EPS of US$0.08 in Q3 2024 to US$236.8 million and basic EPS losses in each quarter of 2025. This has left investors weighing how the...